uniQure N.V. is a biotechnology company developing adeno-associated virus (AAV)-based gene therapies for rare and devastating diseases. The company's approved product, ifezuntirgene inilparvovec, is a gene therapy for hemophilia B, which is commercialized under a license agreement with CSL Behring. Its clinical pipeline includes candidates for Huntington’s disease (AMT-130), refractory mesial temporal lobe epilepsy (AMT-260), Fabry disease (AMT-191), and amyotrophic lateral sclerosis caused by SOD1 mutations (AMT-162). uniQure operates a proprietary commercial-grade manufacturing facility in Lexington, Massachusetts, and serves patients in the United States and Europe. The company was founded in 1998 as Amsterdam Molecular Therapeutics (AMT) Holding N.V.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage uniqure.com
Sector Healthcare IR page uniqure.com/investors-media
Tags
gene therapy, rare diseases, hemophilia, huntington's disease, epilepsy, fabry disease, amyotrophic lateral sclerosis, aav vectors, biologics, ifezuntirgene inilparvovec, AMT-130, AMT-260, AMT-191, AMT-162, AMT-061, AMT-060, Glybera, CSL Behring
Press page —

Metrics

Valuation  
Market cap $ 1.488B
Market cap (USD) $ 1.488B
P/E -6.04
PEG —
P/BV 5.05
P/S 73.81
P/OCF -7.74
P/FCF -7.72
Dividend yield —
Turnover / mcap —
Returns  
ROE -100.0%
ROI -80.0%
ROIC -55.9%
Profit margin -1,236.0%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 17.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 16.098M 27.119M 15.843M 106.483M 524.002M 37.514M 7.281M 11.284M 13.107M 25.098M 10.578M — — —
Net profit -198.971M -239.556M -308.478M -126.789M 329.589M -125.024M -124.201M -83.304M -79.26M -73.374M -82.083M -49.099M -35.514M -18.399M
Free cash flow -178.402M -186.096M -153.083M -162.748M 270.521M -142.099M -104.335M -78.421M -68.731M -87.477M -139K -54.605M -7.246M -14.589M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 23.93 17.66 6.77 22.67 20.74 36.13 71.66 28.82 19.59 5.6 16.54 14.81 — —
Price performance 12m 0.36 1.61 -0.7 0.09 -0.43 -0.5 1.49 0.47 2.5 -0.66 0.12 — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.68M — — — 6.62M — — — — 5.86M
↳ 5y CAGR -2.4%
Borrowings, current (USD) 605,000 1.05M — — — — — — — —
Borrowings, non-current (USD) 19.6M 19.7M 35.5M 36.1M 35.6M 101M 103M 102M 51.3M 49.7M
Lease liabilities (USD) — — — 37M 35.9M 34.8M 40.1M 36.7M 14.7M 13.7M
Cash and deposits (USD) 132M 159M 235M 378M 245M 556M 228M 241M 159M 80.2M
Intangible assets (USD) 8.32M 9.57M 5.2M 5.43M 3.36M 62.7M 58.8M 60.5M 71M 72.8M
Right-of-use assets (USD) — — 19M 26.8M 26.1M 25.6M 32.7M 28.8M 13.6M 12.5M
Net debt (borrowings + leases - cash) (USD) -112M -139M -199M -305M -173M -421M -85.1M -103M -92.9M -16.8M
Cash flow detail
Operating cash flow (USD) -72.2M -64.3M -76M -98.7M -135M 288M -145M -146M -183M -178M
Purchases of property, plant and equipment (USD) -15.3M -4.46M -2.38M -5.65M -7.27M -17.4M -17.7M -7.15M -3.37M -439,000
Purchases of intangible assets (USD) -1.88M -1.12M -1.86M -996,000 -2.21M — — — — —
Change in inventories (cash effect) (USD) 480,000 — — — — — -6.92M -6.74M 2.42M —
Change in payables (cash effect) (USD) 344,000 -1.67M 1.07M 1.65M -2.7M -727,000 9.24M -4.17M 1.52M -2.67M
Interest paid (cash effect) (USD) -2.35M -1.62M -2.14M -3.12M -4.13M -6.54M -9.25M -16.9M -20.6M -25.1M
Income taxes paid (cash effect) (USD) — — — — — — — -12,000 -21,000 -7.54M
Share-based compensation (USD) 6.21M 10.3M 10.7M 17.5M 21.8M 25.6M 34.2M 35.1M 22.3M 17.7M
Free cash flow (OCF - PPE - intangibles) (USD) -89.4M -69.9M -80.3M -105M -144M 271M -163M -153M -186M -178M
Income detail
Research and development expense (USD) 72.5M 72.2M 74.8M 94.7M 122M 144M 198M 215M 144M 141M
↳ 5y CAGR +14.6% +22.3% +23.5% +8.7% +2.8%
Total comprehensive income (USD) -73.1M -76.5M -88.6M -124M -108M 291M -156M -304M -239M -204M
Comprehensive income to owners (USD) -73.1M -76.5M -88.6M -124M -108M 291M -156M -304M -239M -204M
Reported Mar 15, 2017 Mar 14, 2018 Apr 29, 2020 Mar 1, 2021 Mar 1, 2021 Feb 25, 2022 Feb 27, 2023 Mar 2, 2026 Mar 2, 2026 May 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026

PDF Version

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~

~ Aligned with FDA on key elements of confirmatory study design; U.S. patient screening expected to begin by end of 2026 ~

~ Cash, cash equivalents and investment securities of approximately $768.4 million as of September 30, 2026 expected to fund operations into 2030 ~

~ uniQure to host earnings call at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2026 and highlighted recent progress across its business.

“Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease,” said Matthew Kapusta, chief executive officer at uniQure. “We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.”

"As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans,” Mr. Kapusta continued. “We are grateful to the patients, families and investigators who have made this progress possible, and are honored to continue to work alongside this community."

Recent Company Developments and Updates

Advancing ifezuntirgene inilparvovec towards potential accelerated approval for the treatment of Huntington’s disease

  • In November 2026, the U.S. Food and Drug Administration (FDA) accepted for review the Company’s Biologics License Application (BLA) for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway. The BLA was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.

  • In September 2026, the Company announced additional data from its ongoing Phase I/II studies with a data cutoff of June 30, 2026.

  • In the 12 high-dose patients with 48 months of follow-up, composite Unified Huntington’s Rating Scale (cUHDRS), the pre-specified primary endpoint for the analysis, showed a 44% slowing of disease progression versus the updated external control (non-significant p=0.144). Total Functional Capacity (TFC), the primary measure for the confirmatory study, showed a 61% slowing (nominal p=0.008) at 48 months. At 48-months, high-dose patients compared to low-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC, consistent with a dose-dependent treatment effect. Cerebrospinal fluid neurofilament light chain (NfL) remained near baseline at 48 months.

  • An updated 36-month analysis including all 15 high-dose patients showed an 80% slowing on cUHDRS (nominal p=0.005) and a 67% slowing on TFC (nominal p=0.011).

  • Ifezuntirgene inilparvovec was generally well tolerated with a manageable safety profile across 51 total treated patients.

  • The Company and the FDA reached alignment on key elements of the confirmatory study of ifezuntirgene inilparvovec. The study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months. The Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.

  • In the third quarter of 2026, the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) validated the Marketing Authorization Application (MAA) for ifezuntirgene inilparvovec, which was submitted to the MHRA earlier in the quarter.

  • The Company continues to advance its launch readiness activities, including the build out of its field medical, market access, and strategic account teams as well as engagement with U.S. Huntington’s disease treatment centers.

Continued clinical progress in pipeline programs

AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE)

  • In the third quarter of 2026, the Company completed enrollment in the second dose cohort of seven patients in the ongoing Phase I/IIa study and expects to present updated results in the first half of 2027.

AMT-191 for the treatment of Fabry disease

  • In August 2026, enrollment resumed in the mid- and high-dose cohorts of the ongoing Phase I/II study of AMT-191 in Fabry disease. Per protocol, dosing had previously been paused after observing asymptomatic liver enzyme elevations in two mid-dose patients, which resolved following a course of immunosuppression.

  • The Company expects to present updated results from the Phase I/II study in all dosing cohorts in the first half of 2027.

Focused execution and strong financial position

  • As of September 30, 2026, the Company had cash, cash equivalents and investment securities of $768.4 million. The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.

Financial Highlights

Cash Position: As of September 30, 2026, the Company held $768.4 million in cash, cash equivalents and investment securities, compared to $622.5 million as of December 31, 2025. The Company expects that these resources will be sufficient to fund projected operating expenses into 2030.

Revenues: Revenue for the three months ended September 30, 2026 was $5.2 million, compared to $3.7 million in the same period in 2025. The increase of $1.5 million is due to an increase in license revenue, compared to the prior period.

R&D Expenses: Research and development expenses were $35.5 million for the three months ended September 30, 2026, compared to $34.4 million in the same period in 2025. The $1.1 million increase primarily resulted from a $3.6 million increase in employee and contractor-related expenses including share-based compensation partially offset by a $2.3 million decrease in direct research and development expenses. The decrease in direct research and development expenses resulted from a $4.1 million reduction in process validation expenses related to ifezuntirgene inilparvovec, a $1.5 million increase in expenses related to AMT-260 and a $1.7 million increase in expenses related to preclinical activities and technology innovation projects.

SG&A Expenses: Selling, general and administrative expenses were $23.9 million for the three months ended September 30, 2026, compared to $19.4 million during the same period in 2025. The $4.5 million increase was primarily related to a $3.0 million increase in employee and contractor-related expenses, including share-based compensation, mainly as a result of the recruitment efforts over the last 12 to 15 months, a $0.7 million increase in professional fees and a $0.7 million increase in information technology costs to support the potential commercial launches of ifezuntirgene inilparvovec.

Non-Operating Items, net: Other non-operating items, net was an expense of $7.6 million for the three months ended September 30, 2026, compared to an expense of $20.9 million during the same period in 2025. The $13.3 million decrease in net non-operating expense was primarily due to $6.3 million reduction of expenses related to pre-funded warrants as well as $6.8 million improvement of net interest income.

Net loss: The net loss for the three months ending September 30, 2026, was $61.2 million, or $0.88 basic and diluted loss per ordinary share, compared to $80.5 million net loss for the comparative period in 2025, or $1.38 basic and diluted loss per ordinary share.

Upcoming investor events:

  • Guggenheim 3rd Annual Healthcare Conference, November 10 – Boston, MA

  • Stifel 2026 Healthcare Conference, November 11 – New York, NY

  • UBS Global Biopharma Conference 2026 – November 16 – London, England

Investor Conference Call and Webcast Information

uniQure management will host an investor conference call and webcast today, Wednesday, November 4th at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s cash runway and its ability to fund its operations into 2030; its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression based on the Company’s evaluation and view of certain measurements of disease progression the Company’s ability and plans to strategically advance its programs, including the potential commercialization of ifezuntirgene inilparvovec; the Company’s future interactions with regulatory authorities and regulatory updates related to ifezuntirgene inilparvovec ; the Company’s plans and ability to conduct a confirmatory study for ifezuntirgene inilparvovec , including the design, timing, endpoints and control arm of such study; ; and the Company’s plans to attend upcoming investor events. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company’s programs, including the risk that clinical results will be unable to demonstrate data sufficient to support further clinical development or regulatory approval in any country where approval is pursued; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of ifezuntirgene inilparvovec; the risk that the FDA ultimately concludes that the Phase I/II trial data for ifezuntirgene inilparvovec are not sufficient to support approval of ifezuntirgene inilparvovec; the Company’s interactions with regulatory authorities, including the FDA and MHRA, which may affect the initiation, timing and progress of clinical trials and pathways and timing for regulatory approval for the Company’s other clinical candidates; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec ; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec ; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

| uniQure Contacts: |

| | | |

| FOR INVESTORS: | | FOR MEDIA: |

| Chiara Russo | | Tom Malone |

| Direct: 781-491-4371 | | Direct: 339-970-7558 |

| Mobile: 617-306-9137 | | Mobile:339-223-8541 |

| [email protected] | | [email protected] |

| uniQure N.V. |

| |

| UNAUDITED CONSOLIDATED BALANCE SHEETS |

| |

| | September 30, | | December 31, | | | | |

| | | 2026 | | | 2025 | | | | |

| | (in thousands, U.S. dollars) | | | | |

| Current assets | | | | | | | |

| Cash and cash equivalents | $ | 98,442 | | $ | 80,240 | | | | |

| Current investment securities | | 570,021 | | | 542,301 | | | | |

| Accounts receivable | | 4,804 | | | 5,863 | | | | |

| Prepaid expenses | | 9,601 | | | 20,506 | | | | |

| Other current assets and receivables | | 9,677 | | | 7,076 | | | | |

| Total current assets | | 692,545 | | | 655,986 | | | | |

| Non-current assets | | | | | | | |

| Property, plant and equipment, net | $ | 9,923 | | $ | 13,800 | | | | |

| Other investments | | 31,539 | | | 30,237 | | | | |

| Non-current investment securities | | 99,967 | | | - | | | - | |

| Operating lease right-of-use assets | | 10,980 | | | 12,525 | | | | |

| Intangible assets, net | | 61,855 | | | 72,790 | | | | |

| Goodwill | | 24,503 | | | 25,355 | | | | |

| Deferred tax assets, net | | 5,709 | | | 8,654 | | | | |

| Other non-current assets | | 3,530 | | | 5,561 | | | | |

| Total non-current assets | | 248,006 | | | 168,922 | | | | |

| Total assets | $ | 940,551 | | $ | 824,908 | | | | |

| Current liabilities | | | | | | | |

| Accounts payable | $ | 6,173 | | $ | 5,170 | | | | |

| Accrued expenses and other current liabilities | | 50,979 | | | 41,292 | | | | |

| Liability related to pre-funded warrants | | - | | | 12,595 | | | | |

| Current portion of operating lease liabilities | | 2,990 | | | 3,862 | | | | |

| Total current liabilities | | 60,142 | | | 62,919 | | | | |

| Non-current liabilities | | | | | | | |

| Long-term debt | | 50,345 | | | 49,699 | | | | |

| Liability from royalty financing agreement | | 497,271 | | | 473,199 | | | | |

| Operating lease liabilities, net of current portion | | 9,032 | | | 9,832 | | | | |

| Contingent consideration | | 18,742 | | | 18,736 | | | | |

| Deferred tax liability, net | | 7,699 | | | 7,967 | | | | |

| Other non-current liabilities, net of current portion | | 2,667 | | | 3,655 | | | | |

| Total non-current liabilities | | 585,756 | | | 563,088 | | | | |

| Total liabilities | | 645,898 | | | 626,007 | | | | |

| Shareholders' equity | | | | | | | |

| Total shareholders' equity | | 294,653 | | | 198,901 | | | | |

| Total liabilities and shareholders' equity | $ | 940,551 | | $ | 824,908 | | | | |

| | | | | | | | |

| uniQure N.V. |

| |

| UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS |

| | | | | |

| | Three months ended September 30, | |

| | | 2026 | | | | 2025 | | |

| | (in thousands, U.S dollars, except share and per share amounts) | |

| Total revenues | $ | 5,196 | | | $ | 3,701 | | |

| Operating expenses: | | | | |

| Cost of license revenues | | (236 | ) | | | (398 | ) | |

| Research and development expenses | | (35,517 | ) | | | (34,366 | ) | |

| Selling, general and administrative expenses | | (23,918 | ) | | | (19,438 | ) | |

| Total operating expenses | | (59,671 | ) | | | (54,202 | ) | |

| Other income | | 1,690 | | | | 1,510 | | |

| Other expense | | (195 | ) | | | (2,044 | ) | |

| Loss from operations | | (52,980 | ) | | | (51,035 | ) | |

| Non-operating items, net | | (7,561 | ) | | | (20,868 | ) | |

| Loss before income tax expense | $ | (60,541 | ) | | $ | (71,903 | ) | |

| Income tax expense | | (676 | ) | | | (8,626 | ) | |

| Net loss | $ | (61,217 | ) | | $ | (80,529 | ) | |

| | | | | |

| Basic and diluted net loss per ordinary share | $ | (0.88 | ) | | $ | (1.38 | ) | |

| Weighted average shares used in computing basic and diluted net loss per ordinary share | | 69,900,863 | | | | 58,516,415 | | |

| | | | | |

Primary Logo

November 2, 2026

PDF Version

~ FDA sets PDUFA target action date of May 1, 2027 ~

~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment for Huntington’s disease ~

LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting. The Company will be notified once the date and timelines have been finalized.

“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease," stated Matt Kapusta, chief executive officer of uniQure. "Backed by compelling data from our Phase I/II studies, we believe ifezuntirgene inilparvovec has the potential to become the first disease modifying treatment for Huntington’s disease. With the FDA’s priority review underway, we will work in conjunction with the Agency, clinicians, and the Huntington’s community to support the review process. The confirmatory trial remains a key priority, with screening anticipated to begin by year end and the study is expected to be well underway by the time of potential approval.”

The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database, as previously announced on September 24, 2025.

The Company and FDA have aligned on key elements of the confirmatory study design. The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) as the primary endpoint at 36 months. The Company plans to initiate patient screening in the U.S. by the end of 2026.

Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.1, EU2, and the UK3, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "expect," "intend," "look forward to," "may," "plan," "potential," “seek,” "should," "will" and similar expressions and the negatives of those terms. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the review and approval of its biologics license application (“BLA”) for ifezuntirgene inilparvovec; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of, ifezuntirgene inilparvovec; whether the FDA will hold an advisory committee to discuss the BLA and the timing of such review and approval based on the Prescription Drug User Fee Act (“PDUFA”) target action date of May 1, 2027 for the BLA; and its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression based on the Company’s evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: the risk that the FDA ultimately concludes that the Phase I/II trial data and/or the confirmatory trial data are not sufficient to support accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the pathways to regulatory approval; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; and the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

| FOR INVESTORS: | FOR MEDIA: |

| | |

| Chiara Russo | Tom Malone |

| Direct: 781-491-4371 | Direct: 339-970-7558 |

| Mobile: 617-306-9137 | Mobile:339-223-8541 |

| [email protected] | [email protected] |

1 Yohrling G, et al. Neurology 2020;94(15 Suppl):954. 2 Medina A, et al. Mov Disord 2022;37(12):2327–2335 3 Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.

Primary Logo

October 28, 2026

PDF Version

~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2026 financial results before market open on Wednesday, November 4, 2026. Management will then host a conference call at 8:30 a.m. ET.

The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:

| FOR INVESTORS: | FOR MEDIA: |

| | |

| Chiara Russo | Tom Malone |

| Direct: 781-491-4371 | Direct: 339-970-7558 |

| Mobile: 617-306-9137 | Mobile:339-223-8541 |

| [email protected] | [email protected] |

Primary Logo

Prompts

uniQure N.V. (ticker QURE), listed in United States.

Company History

Date Change Detail
Dec 31, 2015 Reporting currency Its US reports are in USD instead of EUR from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.

ETFs Holding uniQure N.V.

ETF Weight in ETF Shares Market value As of
JGRO 0.10% 415,593 $ 8.636M Nov 17, 2026
AVSC 0.00% 52 $ 1,137.76 Nov 16, 2026